Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy*

Author:

Miyamoto Toshihiro1,Sanford David2,Tomuleasa Ciprian3,Hsiao Hui-Hua4,Olivera Leonardo José Enciso5,Enjeti Anoop Kumar6,Gimenez Conca Alberto7,Castillo Teresa Bernal del8ORCID,Girshova Larisa9,Martelli Maria Paola10,Guvenc Birol11,Delgado Alexander12,Duan Yinghui13,Garbayo Guijarro Belen14,Llamas Cynthia13,Lee Je-Hwan15

Affiliation:

1. Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

2. Leukemia/Bone Marrow Transplant Program of BC, Division of Hematology, The University of British Columbia, Vancouver, BC, Canada

3. Department of Hematology – Medfuture Research Center for Advanced Medicine, Ion Chiricuta Clinical Cancer Center, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

4. Department of Internal Medicine, Division of Hematology-Oncology, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung, Taiwan

5. Instituto Nacional de Cancerología, Bogotá, Colombia

6. Calvary Mater Newcastle, University of Newcastle and New South Wales Health Pathology, Waratah, Australia

7. Section of Hematology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

8. Servicio de Hematología y Hemoterapia, University Hospital Central de Asturias, ISPA, IUOPA, Oviedo, Spain

9. Federal State Budgetary Institution ‘Almazov National Medical Research Centre’ of the Ministry of Health of the Russian Federation, St. Petersburg, Russia

10. Department of Medicine and Surgery – Section of Hematology and Clinical Immunology, Perugia University, ‘Santa Maria della Misericordia’ Hospital, Perugia, Italy

11. Department of Hematology, Faculty of Medicine, Cukurova University, Adana, Turkey

12. AbbVie, Inc., Singapore, Singapore

13. AbbVie, Inc., North Chicago, IL, USA

14. AbbVie, Inc., Madrid, Spain

15. Department of Hematology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea

Funder

AbbVie

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3